Table 1.
Baseline characteristics of patients suffering from ICM and dilated cardiomyopathy (DCM)
| ICM | DCM | P | |
|---|---|---|---|
| Age | 64+2 | 55+1 | <.001* |
| BMI | 28+1 | 29+1 | .41 |
| Ejection fraction (%) | 38+2 | 36+2 | .41 |
| LVEDd (mm) | 59+1 | 59+1 | .62 |
| Cholesterol (mg/dL) | 152+10 | 182+9 | .04 |
| LDL (mg/dL) | 81+9 | 107+7 | .03* |
| HDL (mg/dL) | 39+3 | 43+2 | .26 |
| LDL/HDL ratio | 2.2+0.2 | 2.6+0.1 | .13 |
| Triglycerides (mg/dL) | 209+49 | 177+22 | .50 |
| c‐reactive protein | 4.8+1.1 | 6.8+1.5 | .44 |
| BNP (pg/mL) | 448.9+76.4 | 734.1+127.8 | .06 |
| Heart rate (bpm) | 66+2 | 74+2 | .13 |
| Creatinine (μmol/L) | 109.8+6.9 | 99.1+4.1 | .16 |
| Urea (mmol/L) | 9.1+1.0 | 8.2+0.7 | .45 |
| Thrombocytes (×109/L) | 199.4+7.0 | 211.4+6.0 | .19 |
| Leucocytes (×109/L) | 7.4+0.3 | 7.7+0.2 | .26 |
| Symptoms since (months) | 14+3 | 15+3 | .70 |
| Betablocker | 100% | 100% | 1.00 |
| ACE‐I/Sartans | 96% | 92% | .46 |
| Aldosteron antagonists | 63% | 66% | .85 |
| Diuretics | 79% | 91% | .11 |
| NYHA I | 33% | 29% | .26 |
| NYHA II | 39% | 27% | .23 |
| NYHA III | 23% | 30% | .41 |
| NYHA IV | 5% | 14% | .22 |
| Edema | 27% | 25% | .83 |
| Angina pectoris | 8% | 3% | .40 |
| Adiposity | 35% | 41% | .55 |
| Smoking | 41% | 50% | .34 |
| Arterial hypertension | 77% | 43% | .001* |
| Type 2 diabetes mellitus | 37% | 38% | 1.00 |
indicates statistical significance.